TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intravenous Oxytocin Use to Decrease Blood Loss During Cesarean Section. What is the Optimal Dose: A Randomized Blinded Trial
Brief Summary: The goal of this study is to determine the best dose of a drug called oxytocin, that is usually used to stop bleeding during a delivery, when used during a cesarean delivery. It will be administered during cesarean section in order to decrease the amount blood loss. The investigators are proposing to have 3 groups of subjects each given a different safe dose of oxytocin and then to assess the effectiveness of each regimens on the amount blood lost during cesarean sections.This will let use know which is the best lowest dose needed.


Options:
A: Arm Label: oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: oxytocin2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: oxytocin3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): oxytocin, oxytocin2, oxytocin3
B: Arm Label: Carbetocin 20mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 40mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 60mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 80mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 100mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 20mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 40mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 60mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 80mcg | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 100mcg
C: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol, PLACEBO
D: Arm Label: OCT-group; Type: N/A; Interventions: N/A | Arm Label: None-OCT-group; Type: N/A; Interventions: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Confirming the Efficacy and Safety of Genz-112638 in Patients With Gaucher Disease Type 1 (ENGAGE)
Brief Summary: This Phase 3 study was designed to confirm the efficacy and safety of eliglustat tartrate (Genz-112638) in participants with Gaucher disease Type 1.


Options:
A: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Eliglustat tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Eliglustat tartrate; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 60 Units/kg; Type: EXPERIMENTAL; Interventions: Drug: Taliglucerase alfa | Arm Label: 30 Units/kg; Type: EXPERIMENTAL; Interventions: Drug: Taliglucerase alfa | Intervention Type: DRUG; Name: Taliglucerase alfa; Assigned to Arm(s): 30 Units/kg, 60 Units/kg
C: Arm Label: prGCD 30 Units/kg; Type: EXPERIMENTAL; Interventions: Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD) | Arm Label: prGCD 60 Units/kg; Type: EXPERIMENTAL; Interventions: Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD) | Intervention Type: DRUG; Name: Plant cell expressed recombinant glucocerebrosidase (prGCD); Assigned to Arm(s): prGCD 30 Units/kg | Intervention Type: DRUG; Name: Plant cell expressed recombinant glucocerebrosidase (prGCD); Assigned to Arm(s): prGCD 60 Units/kg
D: Arm Label: 30 units/kg; Type: EXPERIMENTAL; Interventions: Drug: Taliglucerase alfa | Arm Label: 60 units/kg; Type: EXPERIMENTAL; Interventions: Drug: Taliglucerase alfa | Intervention Type: DRUG; Name: Taliglucerase alfa; Assigned to Arm(s): 30 units/kg, 60 units/kg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Confirming the Efficacy and Safety of Genz-112638 in Patients With Gaucher Disease Type 1 (ENGAGE)
Brief Summary: This Phase 3 study was designed to confirm the efficacy and safety of eliglustat tartrate (Genz-112638) in participants with Gaucher disease Type 1.


Options:
A: Arm Label: Insulin glargine + omega-3 polyunsaturated fatty acids; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (HOE901), Drug: omega-3 polyunsaturated fatty acids (PUFA), Device: reusable pen device for insulin injection | Arm Label: Insulin glargine + placebo; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (HOE901), Drug: placebo, Device: reusable pen device for insulin injection | Arm Label: Standard care + omega-3 polyunsaturated fatty acids; Type: EXPERIMENTAL; Interventions: Drug: omega-3 polyunsaturated fatty acids (PUFA) | Arm Label: Standard care + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: insulin glargine (HOE901); Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Insulin glargine + placebo | Intervention Type: DRUG; Name: omega-3 polyunsaturated fatty acids (PUFA); Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Standard care + omega-3 polyunsaturated fatty acids | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Insulin glargine + placebo, Standard care + placebo | Intervention Type: DEVICE; Name: reusable pen device for insulin injection; Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Insulin glargine + placebo
B: Arm Label: prGCD 30 Units/kg; Type: EXPERIMENTAL; Interventions: Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD) | Arm Label: prGCD 60 Units/kg; Type: EXPERIMENTAL; Interventions: Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD) | Intervention Type: DRUG; Name: Plant cell expressed recombinant glucocerebrosidase (prGCD); Assigned to Arm(s): prGCD 30 Units/kg | Intervention Type: DRUG; Name: Plant cell expressed recombinant glucocerebrosidase (prGCD); Assigned to Arm(s): prGCD 60 Units/kg
C: Arm Label: Eliglustat tartrate; Type: EXPERIMENTAL; Interventions: Drug: Eliglustat tartrate | Intervention Type: DRUG; Name: Eliglustat tartrate; Assigned to Arm(s): Eliglustat tartrate
D: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Eliglustat tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Eliglustat tartrate; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Aclidinium Bromide at Two Dose Levels (200 μg Twice Daily, 400 μg Twice Daily) vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The purpose of this study is to assess the efficacy (effectiveness) and safety of aclidinium bromide doses as compared to placebo in the treatment of moderate to severe chronic obstructive pulmonary disease. The study will be 16 weeks in duration; 2-week run-in period, 12-week double-blind treatment, and 2-week follow-up phone visit.


Options:
A: Arm Label: tiotropium + olodaterol low dose; Type: EXPERIMENTAL; Interventions: Drug: tiotropium, Drug: olodaterol | Arm Label: tiotropium + olodaterol high dose; Type: EXPERIMENTAL; Interventions: Drug: tiotropium, Drug: olodaterol | Arm Label: tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: tiotropium | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): tiotropium + olodaterol high dose | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: olodaterol; Assigned to Arm(s): tiotropium + olodaterol high dose | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): tiotropium + olodaterol low dose | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): tiotropium | Intervention Type: DRUG; Name: olodaterol; Assigned to Arm(s): tiotropium + olodaterol low dose
B: Arm Label: Olodaterol andTiotropium; Type: EXPERIMENTAL; Interventions: Drug: Tiotropium, Drug: Olodaterol | Arm Label: Placebo and Tiotropium; Type: OTHER; Interventions: Drug: Tiotropium, Drug: Placebo matching Olodaterol | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Placebo and Tiotropium | Intervention Type: DRUG; Name: Placebo matching Olodaterol; Assigned to Arm(s): Placebo and Tiotropium | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Olodaterol andTiotropium | Intervention Type: DRUG; Name: Olodaterol; Assigned to Arm(s): Olodaterol andTiotropium
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Aclidinium Bromide at Two Dose Levels (200 μg Twice Daily, 400 μg Twice Daily) vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The purpose of this study is to assess the efficacy (effectiveness) and safety of aclidinium bromide doses as compared to placebo in the treatment of moderate to severe chronic obstructive pulmonary disease. The study will be 16 weeks in duration; 2-week run-in period, 12-week double-blind treatment, and 2-week follow-up phone visit.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
B: Arm Label: Aclidinium; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium Bromide; Assigned to Arm(s): Aclidinium | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Aclidinium 400 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 400 μg bid | Arm Label: Tiotropium 18 μg once-daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium 18 μg once-daily | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide 400 μg bid; Assigned to Arm(s): Aclidinium 400 μg bid | Intervention Type: DRUG; Name: Tiotropium 18 μg once-daily; Assigned to Arm(s): Tiotropium 18 μg once-daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Aclidinium bromide 100 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 100 μg bid | Arm Label: Aclidininum bromide 200 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 200 μg bid | Arm Label: Aclidininum bromide 400 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidininum bromide 400 μg bid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Formoterol 12 μg bid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol 12 μg bid | Intervention Type: DRUG; Name: Aclidinium bromide 100 μg bid; Assigned to Arm(s): Aclidinium bromide 100 μg bid | Intervention Type: DRUG; Name: Aclidinium bromide 200 μg bid; Assigned to Arm(s): Aclidininum bromide 200 μg bid | Intervention Type: DRUG; Name: Aclidininum bromide 400 μg bid; Assigned to Arm(s): Aclidininum bromide 400 μg bid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Formoterol 12 μg bid; Assigned to Arm(s): Formoterol 12 μg bid

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Aclidinium Bromide at Two Dose Levels (200 μg Twice Daily, 400 μg Twice Daily) vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The purpose of this study is to assess the efficacy (effectiveness) and safety of aclidinium bromide doses as compared to placebo in the treatment of moderate to severe chronic obstructive pulmonary disease. The study will be 16 weeks in duration; 2-week run-in period, 12-week double-blind treatment, and 2-week follow-up phone visit.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
B: Intervention Type: DRUG; Name: Formoterol; Assigned to Arm(s): N/A
C: Intervention Type: DEVICE; Name: 5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler; Assigned to Arm(s): N/A
D: Arm Label: Glycopyrronium bromide; Type: EXPERIMENTAL; Interventions: Drug: Glycopyrronium bromide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Glycopyrronium bromide; Assigned to Arm(s): Glycopyrronium bromide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2 Randomized, Controlled, Open-label Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without EGFR Mutations
Brief Summary: This study is a prospective trial of Alimta (pemetrexed) versus IRESSA (gefitinib) among epidermal growth factor receptor wild-type Non-Small Cell Lung Cancer (NSCLC) patients in a 2nd line setting.


Options:
A: Arm Label: Pemetrexed + Cisplatin + Gefitinib; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed, Drug: Cisplatin, Drug: Gefitinib | Arm Label: Gefitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gefitinib | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Pemetrexed + Cisplatin + Gefitinib | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Pemetrexed + Cisplatin + Gefitinib | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): Pemetrexed + Cisplatin + Gefitinib | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): Gefitinib
B: Arm Label: Alimta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pemetrexed (Alimta) | Arm Label: IRESSA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gefitinib (IRESSA) | Intervention Type: DRUG; Name: Pemetrexed (Alimta); Assigned to Arm(s): Alimta | Intervention Type: DRUG; Name: Gefitinib (IRESSA); Assigned to Arm(s): IRESSA
C: Arm Label: gefitinib; Type: EXPERIMENTAL; Interventions: Drug: Gefitinib | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): gefitinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Gefitinib | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mindfulness Training for Stress Management: A Two-centre Randomised Controlled Study of Medical and Psychology Students With Long-term Follow up
Brief Summary: This study will assess the short and long term effects of a group-based mindfulness programme (Mindfulness-Based Stress Reduction, MBSR) on first year medical and psychology students at the Universities of Oslo and Tromso.

The primary outcome variables are mental distress, student stress and subsequent work stress, subjective wellbeing, empathy, mindfulness and spirituality. The investigators will also study explanatory moderator and mediator variables.

The study will be a two-centre randomized controlled study involving 288 medical and psychology students from the University of Oslo and from the University of Tromso. The sample size calculation is based on a reduction in mental distress and perceived medical/psychology school stress of 20% in the intervention group. The control group will not receive an intervention. After the initial seven week course (taking place in 2009 and 2010) the intervention group will receive a follow-up session of 1.5 hours twice a year throughout their study course of 5-6 years. The follow-up period will last until 1 year after graduation in the Oslo cohort and until 3 years after graduation in the Tromso cohort.


Options:
A: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: Control | Arm Label: Acceptance and Commitment Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Acceptance and Commitment Therapy | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control | Intervention Type: BEHAVIORAL; Name: Acceptance and Commitment Therapy; Assigned to Arm(s): Acceptance and Commitment Therapy
B: Arm Label: Mindfulness training; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindfulness training; Assigned to Arm(s): Mindfulness training
C: Arm Label: Face-to-face group-based mindfulness; Type: EXPERIMENTAL; Interventions: Behavioral: Face-to-face group-based mindfulness | Arm Label: Internet-based mindfulness; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based mindfulness | Arm Label: Waiting-list control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Face-to-face group-based mindfulness; Assigned to Arm(s): Face-to-face group-based mindfulness | Intervention Type: BEHAVIORAL; Name: Internet-based mindfulness; Assigned to Arm(s): Internet-based mindfulness
D: Arm Label: Passive control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Planned intervention - mantra meditation; Type: EXPERIMENTAL; Interventions: Behavioral: Mantra Meditation | Intervention Type: BEHAVIORAL; Name: Mantra Meditation; Assigned to Arm(s): Planned intervention - mantra meditation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mindfulness Training for Stress Management: A Two-centre Randomised Controlled Study of Medical and Psychology Students With Long-term Follow up
Brief Summary: This study will assess the short and long term effects of a group-based mindfulness programme (Mindfulness-Based Stress Reduction, MBSR) on first year medical and psychology students at the Universities of Oslo and Tromso.

The primary outcome variables are mental distress, student stress and subsequent work stress, subjective wellbeing, empathy, mindfulness and spirituality. The investigators will also study explanatory moderator and mediator variables.

The study will be a two-centre randomized controlled study involving 288 medical and psychology students from the University of Oslo and from the University of Tromso. The sample size calculation is based on a reduction in mental distress and perceived medical/psychology school stress of 20% in the intervention group. The control group will not receive an intervention. After the initial seven week course (taking place in 2009 and 2010) the intervention group will receive a follow-up session of 1.5 hours twice a year throughout their study course of 5-6 years. The follow-up period will last until 1 year after graduation in the Oslo cohort and until 3 years after graduation in the Tromso cohort.


Options:
A: Arm Label: Mindfulness training; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindfulness training; Assigned to Arm(s): Mindfulness training
B: Arm Label: Short-term Compassion Fatigue Resiliency Program; Type: EXPERIMENTAL; Interventions: Behavioral: Compassion Fatigue Resiliency Program (CFRP) | Arm Label: Long-term Compassion Fatigue Resiliency Program; Type: EXPERIMENTAL; Interventions: Behavioral: Compassion Fatigue Resiliency Program (CFRP) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Compassion Fatigue Resiliency Program (CFRP); Assigned to Arm(s): Long-term Compassion Fatigue Resiliency Program, Short-term Compassion Fatigue Resiliency Program
C: Arm Label: Mobile Video Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Stress management counseling | Arm Label: Offline Counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Stress management counseling | Arm Label: Selfcare; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Stress management counseling; Assigned to Arm(s): Mobile Video Counseling, Offline Counseling
D: Arm Label: Electronic intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Electronic intervention suggesting behavioral activity | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Electronic intervention suggesting behavioral activity; Assigned to Arm(s): Electronic intervention

Answer: A